MAY 2017 Deal Watch Review AVAILABLE NOW.
Jill has over 25 years’ experience in the biopharmaceutical, healthcare and drug delivery industries, combining broad commercial experience with a strong scientific background.
Her key skills and achievements include:
Jill has a PhD in Genetics and spent five years in research at the Universities of Edinburgh and Oxford before joining Delta Biotechnology (now Novozymes Biopharma) in 1987. At Delta she held various R&D and project management positions. On leaving Delta in 1993, Jill co-founded a consultancy business specialising in the biopharmaceutical industry where she was involved in a range of projects for US and European clients.
In 1996, Jill took up a business development role with one of her clients, Andaris. During the next 4 years, she was involved in two separate acquisitions: Andaris was first acquired by Quadrant Healthcare and then the enlarged Quadrant was acquired by Elan Corporation. Throughout this time, Jill was involved in numerous licensing and product and technology divestment activities and finalised a range of deals on early stage products and technology platforms.
In 2003 Jill joined pSivida, an Australian NASDAQ-listed company, where she was Commercial Director with a broad range of business responsibilities, including the out-licensing of the company’s lead oncology product, BrachySil™. Since leaving pSivida in early 2007, Jill has been a business development consultant working with a range of international clients in numerous therapeutic and technology areas, including diabetes and obesity, respiratory disease, women’s health, anti-infectives, haemato-oncology and biologicals for various indications. Until recently Jill was a Board Director of Warwick Effect Polymers and its part time VP of Business Development, playing a leading role in its acquisition by PolyTherics in early 2012.